Tarix, Unigene deal
Tarix exercised an option to license exclusive, worldwide rights to Unigene's Peptelligence drug delivery technology for use with angiotensin I-VII and its functional equivalents, analogs and derivatives. Angiotensin is the pharmaceutical ingredient in Tarix's TXA127, a peptide that stimulates early hematopoietic precursor cells in the bone marrow. Tarix gained the option in February when the partners entered a feasibility deal to evaluate an oral formulation of TXA127 formulated using the Peptelligence technology. Unigene is eligible for an undisclosed percentage of sales of products as well as an undisclosed percentage of upfront and milestone payments, and royalties from a third-party licensing deal. The companies declined to disclose details. ...